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BACKGROUND: Controversy exists as to whether patients with thick (Breslow depth >4 mm), clinically
lymph node-negative melanoma require sentinel lymph node (SLN) biopsy. The authors examined the
impact of SLN biopsy on prognosis and outcome in this patient population. METHODS: A review of the
authors’ institutional review board-approved melanoma database identified 293 patients with T4 melanoma
who underwent surgical excision between 1998 and 2007. Patient demographics, histologic features, and
outcome were recorded and analyzed. RESULTS: Of 227 T4 patients who had an SLN biopsy, 107 (47%)
were positive. The strongest predictors of a positive SLN included angiolymphatic invasion, satellitosis, or
ulceration of the primary tumor. Patients with a T4 melanoma and a negative SLN had a significantly better
5-year distant disease-free survival (DDFS) (85.3% vs 47.8%; P < .0001) and overall survival (OS) (80% vs
47%; P < .0001) compared with those with metastases to the SLN. For SLN-positive patients, only angio-
lymphatic invasion was a significant predictor of DDFS, with a hazard ratio of 2.29 (P¼.007). Ulceration
was not significant when examining SLN-positive patients but the most significant factor among SLN-nega-
tive patients, with a hazard ratio of 5.78 (P¼.02). Increasing Breslow thickness and mitotic rate were also
significantly associated with poorer outcome. Patients without ulceration or SLN metastases had an
extremely good prognosis, with a 5-year OS >90% and a 5-year DDFS of 95%. CONCLUSIONS: Clinically
lymph node-negative T4 melanoma cases should be strongly considered for SLN biopsy, regardless of Bre-
slow depth. SLN lymph node status is the most significant prognostic sign among these patients. T4
patients with a negative SLN have an excellent prognosis in the absence of ulceration and should not be
considered candidates for adjuvant high-dose interferon. Cancer 2009;115:5752–60. VC 2009 American
Cancer Society.
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The preliminary results from the Multicenter Selective Lymphadenectomy Trial-I represent the first
randomized prospective clinical trial to reveal a potential survival advantage to performing sentinel lymph
node (SLN) biopsy in patients with malignant melanoma. However, these results were limited to patients
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with intermediate-thickness melanoma.1 Controversy
continues to surround the use of SLN biopsy in
patients with both thin (<1.0 mm in Breslow thick-
ness) and thick melanoma (4.0 mm in Breslow thick-
ness). For patients with thin melanoma, the discussion
has centered around identifying a subset of these
patients who may still benefit from SLN biopsy.2-8 For
patients with thick melanoma, there remains contro-
versy as to whether SLN biopsy is beneficial.
The arguments for performing SLN biopsy at the
time of wide local excision in any patient with mela-
noma include prognostic and staging information,
implications of SLN status for adjuvant therapy deci-
sions, and the potential therapeutic impact of comple-
tion lymph node dissection in patients with a positive
SLN. However, many clinicians contend that SLN bi-
opsy may not be necessary in patients with thick mela-
noma, because these patients have a high rate of both
regional and systemic occult disease at the time of pre-
sentation.9 Thus, SLN biopsy may not provide signifi-
cant prognostic information beyond Breslow thickness,
nor would completion lymph node dissection have any
significant impact on outcome should the SLN biopsy
be positive. In regard to adjuvant therapy, high-dose
interferon alpha-2b was approved by the US Food and
Drug Administration (FDA) in 1995 for adjuvant ther-
apy of both lymph node-positive and T4 lymph node-
negative disease,10 so these patients are already candi-
dates for treatment based on their tumor thickness.
Thus, SLN biopsy may not be necessary for adjuvant
therapy decisions. To shed additional light on this con-
troversy, we examined the impact of SLN biopsy among
patients with melanoma4.0 mm in Breslow thickness.
MATERIALS AND METHODS
This study was approved by the University of Michigan
Institutional Review Board. Our prospectively collected
melanoma database was queried for patients with pri-
mary cutaneous melanoma 4.0 mm in Breslow thick-
ness (American Joint Committee on Cancer [AJCC]
stage T4) who underwent definitive surgical treatment
at the University of Michigan between January of 1997
and December of 2007. After excluding patients with
clinical or radiographic evidence of distant disease, 293
consecutive cases were identified. Our SLN biopsy tech-
nique and method of SLN evaluation has been described
previously.3 All primary lesions and SLN biopsy slides
were reviewed by 1 of 4 dermatopathologists at the Uni-
versity of Michigan, who generated a 14-point mela-
noma profile for the primary lesion. Survival
information was obtained from computerized medical
records and from the Tumor Registry. The local and
disease-free survival (DDFS) were calculated from the
time of definitive surgery. Locoregional recurrence was
defined as any local recurrence, in-transit recurrence, or
regional recurrence within a primary draining lymph
node basin.
Statistical Methods
Patient and tumor characteristics were tested for signifi-
cant association with a positive SLN using the chi-square
and t test for categorical and continuous characteristics,
respectively. Overall survival (OS) and DDFS were calcu-
lated for each patient beginning at the date of surgery.
For OS patients known to be alive were censored on their
last contact date. For DDFS, patients were followed until
date of documented distant disease or death. Patients
known to be alive without intervening distant failure
were also censored on their last contact date. The prod-
uct limit method of Kaplan and Meier was used to esti-
mate survival probabilities, with the population stratified
by the positivity of the sentinel lymph node basin. Cox
proportional hazard models were used to estimate the
bivariate association between survival endpoints and the
available patient and tumor characteristics. Those char-
acteristics found to be significantly associated in bivariate
models were simultaneously modeled, to create a best
multivariate model for both endpoints separately. The
best multivariate model was defined as the model that
resulted from application of a backward elimination
algorithm, whereby the multivariate model was pared
down iteratively, removing sequentially the characteristic
with the highest Wald-type P value, until only significant
characteristics remained. This model schema was also
applied to those cases with negative sentinel lymph nodes
and those with at least 1 positive sentinel lymph node,
separately. Significance for all statistical tests was defined
as a P value<5%.
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RESULTS
Patient Characteristics
The patient characteristics of the study population are
listed in Table 1. The mean age of patients was 58 years,
with a range of 4 to 94 years, including 7 patients under
the age of 16 years. The median Breslow thickness was
5.6 mm, with a range of 4 to 24 mm. Primary tumor dis-
tribution was relatively well distributed between the
trunk, head and neck, and extremities. Six patients had
subungual melanomas. The most common melanoma
histologic pattern subtype was nodular (38%), followed
by superficial spreading (20%), desmoplastic (9%), acral
lentigo (6%), and lentigo maligna (5%). Ulceration was
present in over half of the cases (53%), and angiolym-
phatic invasion was present in nearly 1 quarter (24%).
SLN Status
Of the 293 patients, 18 (6%) presented with clinically evi-
dent regional metastases. Of the remaining 275 patients,
SLN biopsy was performed in 227 (83%). Of the 48 clini-
cally lymph node-negative patients who did not have a
SLN biopsy, 21 did not undergo the procedure based on
the patient’s elderly age and comorbidities. In 17 cases,
the patient and physician opted not to perform SLN
biopsy for undocumented reasons. In 8 patients, a SLN
biopsy was attempted but failed. Two patients had an
elective lymph node dissection (ELND). For patients who
had a successful SLN biopsy, the melanoma mapped to a
single basin in 161 patients, 2 basins in 65, and 3 basins in
2. The median number of harvested SLNs per basin was 2
(range, 1-10).
The SLN was positive in 107 (47%) patients. Fac-
tors associated with a positive SLN are presented in Table
2. There was no association between the year of surgery
and the presence of a positive SLN. Histologic pattern
subtype was significant primarily because patients with a
desmoplastic melanoma had a significantly lower risk of
SLNmetastases (11%), an observation we have previously
reported.11,12 Location of the primary melanoma did
impact the likelihood of a positive SLN, with a lower like-
lihood in melanoma on the head and neck, although this
too may be driven by the high percentage of desmoplastic
melanoma in this region. Among 57 head and neck mela-
nomas undergoing SLN biopsy, 13 (23%) were desmo-
plastic, with a SLN positivity rate of 15% compared
with 35% for nondesmoplastic melanoma. Satellitosis
(P¼ .009), angiolymphatic invasion (P¼ .001), and
ulceration (P¼ .007) were all significantly more likely to
be associated with a positive SLN, whereas sex, mitotic
rate, regression, and neurotropism were not predictive.
Although Breslow thickness is strongly predictive of SLN
positivity, among patients with thick (4.0 mm) melano-
mas, the incidence of a positive SLN did not continue to
rise significantly with increasing thickness.
Sixty-eight patients received high-dose adjuvant
interferon therapy (46 lymph node positive, 18 lymph
node negative, and 2 with an unknown nodal status).
Four recurred while receiving treatment, and therapy was
discontinued secondary to severe side effects in 12. Five
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patients received an experimental vaccine, and 2 under-
went biochemotherapy. One hundred eighty-three
patients received no interferon treatment. Adjuvant ther-
apy data was not available for 37 patients.
Survival
The median follow-up was 43 months. The locoregional
recurrence rate was 22%. For patients with a negative
SLN, the locoregional recurrence rate was 11%, compared
with 34% with a positive SLN. Among the clinically
lymph node-negative patients who did not have an SLN
biopsy, the locoregional recurrence rate was 21%. Among
the 17 cases where the patient and/or physician opted not
to perform SLN biopsy not based on age or comorbidities,
the locoregional recurrence rate was slightly higher
(29%).
The majority of patients were alive without known
melanoma recurrence at the time of last follow-up (174
patients, 59%). Eighty-two (28%) patients developed dis-
tant recurrence. No data regarding DDFS was available for
10 patients. Seventy-one (24%) patients died of melanoma,
33 (11%) died without disease, 11 (4%) were alive with
known recurrence, and died of unknown cause 4 (1%).
The associations between prognostic factors and
both OS and DDFS were studied among patients with
thick melanomas who underwent successful SLN biopsy.
Several factors were associated with OS on univariate anal-
ysis, noted in Table 3, including increasing patient age
Table 2. Association of Patient Characteristics With a











Female 40 (39.0) 38 (38.0) .73
Male 80 (40.4) 69 (35.8)
Patient age at
surgery, mean y (SD)
54.5 (18.0) 53.9 (16.6) .78
Histologic subtype
Nodular 41 (36.6) 37 (33.0) .03
Superficial spreading 19 (32.2) 28 (47.5)
Other 15 (39.5) 14 (36.8)
Desmoplastic 19 (70.4) 3 (11.1)
Acral lentigo 8 (42.1) 8 (42.1)
Lentigo maligna 7 (43.8) 5 (31.3)
Polypoid 3 (25.0) 7 (58.3)
Spitz-like melanoma 5 (50.0) 5 (50.0)
Location
Head and neck 39 (51.3) 17 (22.4) .02
Lower extremity 20 (38.5) 25 (48.1)
Upper extremity 24 (34.3) 21 (30.0)
Trunk 34 (35.8) 44 (46.3)
Breslow depth,
mean mm (SD)
6.5 (2.6) 6.4 (3.2) .84
Mitotic rate, mean
mitoses/mm2 (SD)
6.4 (7.5) 9.3 (7.0) .14
Regression, No. (%)
No 102 (39.5) 98 (38.0) .23*
Yes 13 (43.3) 7 (23.3)
Unknown 2 (40.0) 2 (40.0)
Satellitosis, No. (%)
No 109 (43.4) 87 (34.7) .01
Yes 7 (18.4) 18 (47.4)
Unknown 1 (25.0) 2 (50.0)
Angiolymphatic invasion, No. (%)
No 100 (45.7) 71 (32.4) .001
Yes 16 (22.9) 34 (48.6)
Unknown 1 (25.0) 2 (50.0)
Ulceration, No. (%)
No 64 (47.1) 39 (28.7) .007
Yes 53 (34.2) 67 (43.2)
Unknown 0 1 (50.0)
Neurotropism, No. (%)
No 100 (39.5) 94 (37.2) .45
Yes 16 (44.4) 11 (30.6)
Unknown 1 (25.0) 2 (50.0)
SLN indicates sentinel lymph node; SD, standard deviation.
*Unknown/missing group is excluded from the statistical test.
Table 3. Univariate Associations With Overall Survival,
SLN Biopsy Population
Characteristic P
All Cases PSLN NSLN
Patient’s age at surgery .0046 .0864 .0142
Histologic subtype .4016 .9134 .4290
Location .5000 .1347 .3742
Breslow depth .0060 .0472 .0348
Mitotic rate .0004 .1711 .0005
Regression .2849 .5108 .6805
Satellitosis .0219 .1495 .2678
Angiolymphatic invasion .0002 .0131 .1210
Ulceration .0022 .4344 .0062
Neurotropism .8357 .5654 .7706
Two nodal drainage basins .7105 .2745 .9847
PSLN <.0001
Adjuvant biologic therapy (interferon) .1594 .1024 .0976
SLN indicates sentinel lymph node; PSLN, positive SLN; NSLN, negative
SLN.
SLN Biopsy in T4 Melanoma/Gajdos et al
Cancer December 15, 2009 5755
(P¼ .004), increasing Breslow thickness (P¼ .006),
increasing mitotic rate (P¼ .004), and the presence of sat-
ellitosis (P¼ .02), angiolymphatic invasion (P > .001),
ulceration (P¼ .002), and at least 1 positive SLN (P <
.001). On multivariate analysis, the most significant pre-
dictors of OS in patients with thick primary melanomas
were increasing patient age (P¼ .03), increasing Breslow
thickness (P¼ .003), the presence of at least 1 positive
SLN (P < .001), and the presence of angiolymphatic
invasion (P¼ .006) (Table 4). Figure 1 demonstrates the
Kaplan-Meier OS analysis for patients with thick primary
melanoma stratified by the SLN status. The 5-year OS for
SLN-positive patients was 47% (95% confidence interval
[CI], 35.2-57.8) compared with 80% (95% CI, 70.1-87;
P< .0001) in SLN-negative patients.
We next stratified patients by their SLN status and
examined separately which factors were most prognostic
for SLN-negative patients and SLN-positive patients
(Table 4). On multivariate analysis for SLN-positive
patients, both increasing Breslow thickness and the presence
of angiolymphatic invasion were significant. In contrast, the
most significant predictors of outcome for SLN-negative
patients with thick melanoma were increasing patient age,
increasing Breslow thickness, and the mitotic rate.
We also examined the impact of these prognostic
factors on DDFS. As shown in Table 5, DDFS was signif-
icantly associated with location of the primary melanoma
(P¼ .003), increasing mitotic rate (P¼ .001), increasing
Breslow thickness (P¼ .004), presence of angiolymphatic
invasion (P < .0001), presence of ulceration (P¼ .0002),
and SLN positivity (P< .0001). Although patient age was
a significant predictor of OS, it was not significant when
looking at DDFS. On multivariate analysis, both angio-
lymphatic invasion (P¼ .005) and ulceration (P¼ .009)
maintain significance; the most significant predictor of
DDFS is SLN positivity, with a hazard ratio of 3.95 for at
least 1 positive SLN. Figure 2 demonstrates the Kaplan-
Meier DDFS analysis for patients with thick primary mel-
anoma stratified by SLN status. The 5-year DDFS for
SLN-positive patients was 47.8% (95% CI, 35.9-58.8),
compared with 85.3% in SLN-negative patients (95%CI,
75.1-91.6; P< .0001).
Again, we performed separate analyses for lymph
node-negative and lymph node-positive disease DDFS
(Table 6). For SLN-positive patients, only angiolym-
phatic invasion was a significant predictor of DDFS, with
a hazard ratio of 2.29 (P¼ .007). Ulceration, which was
significant when looking at the entire group, was not sig-
nificant when examining SLN-positive patients. When
analyzing only the thick, SLN-negative patients, ulcera-
tion was the most significant factor, with a hazard ratio of
Table 4. Multivariate Cox Proportional Hazards Models for








Patient’s age at surgery 1.02* 1.002-1.03 .0313
Breslow depth 1.10* 1.03-1.18 .0032
Mitotic rate 1.03* 1.00-1.06 .0577
Positive sentinel lymph
nodes, yes vs no
2.28 1.37-3.77 .0014
Angiolymphatic invasion 2.07 1.23-3.49 .0063
Positive SLN cases only
Breslow depth 1.10* 1.005-1.21 .0396
Angiolymphatic invasion 2.27 1.22-4.21 .0094
Negative SLN cases only
Patient’s age at surgery 1.04* 1.01-1.06 .0074
Breslow depth 1.15* 1.05-1.26 .0022
Mitotic rate 1.07* 1.03-1.10 .0003
SLN indicates sentinel lymph node.
* Hazard ratio for a 1-unit change in the covariate.
FIGURE 1. Kaplan-Meier overall survival analysis for sentinel
lymph node-positive and -negative patients with thick (T4)
primary melanoma is shown.
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5.78 (P¼ .02). Increasing Breslow thickness and mitotic
rate were also significantly associated with poorer out-
come. Figure 3 shows the Kaplan-Meier DDFS for SLN-
negative patients with thick melanoma stratified by the
presence of ulceration, showing the significant impact of
ulceration on outcome (log-rank P value of .0034). Figure
4 represents DDFS for SLN-positive patients with thick
melanoma, demonstrating the poor survival regardless of
ulceration (P¼ .4).
DISCUSSION
These results represent a large single-institution experi-
ence with thick melanoma. SLN biopsy was offered to the
majority of clinically lymph node-negative patients and
was positive in almost half (47%). In this population,
Table 5. Univariate Associations With Distant Failure-Free
Survival, SLN Biopsy Population
Characteristic P
All Cases PSLN NSLN
Patient’s age at surgery .3062 .2174 .8907
Histologic subtype .2508 .8091 .7871
Location .0033 .0269 .2075
Breslow depth .0038 .2074 .0008
Mitotic rate .0010 .1368 .0061
Regression .1561 .9166 .9912
Satellitosis .1332 .2347 .9926
Angiolymphatic invasion <.0001 .0075 .2118
Ulceration .0002 .1169 .0063
Neurotropism .3003 .7276 .7048





SLN indicates sentinel lymph node; PSLN, positive SLN; NSLN, negative
SLN.
FIGURE 2. Kaplan-Meier distant disease-free survival analysis
for sentinel lymph node-positive and -negative patients with
thick (T4) primary melanoma is shown.
Table 6. Multivariate Cox Proportional Hazards Model for








Angiolymphatic invasion 2.18 1.26-3.76 .0052
Ulceration 2.17 1.21-3.87 .0092
Positive sentinel lymph
nodes, yes vs no
3.95 2.11-7.41 <.0001
Positive SLN cases only
Angiolymphatic invasion 2.29 1.25-4.20 .0075
Negative SLN cases only
Breslow depth 1.16* 1.06-1.26 .0007
Mitotic rate 1.05* 1.004-1.09 .0307
Ulceration 5.78 1.24-26.90 .0255
* Hazard ratio for a 1-unit change in the covariate.
FIGURE 3. Kaplan-Meier distant disease-free survival analysis
for ulcerated and nonulcerated sentinel lymph node-negative
patients with thick (T4) primary melanoma is shown.
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angiolymphatic invasion, satellitosis, and ulceration were
predictive of SLN positivity. With a median follow-up of
43 months, patients with a T4 melanoma and a negative
SLN had a significantly better 5-year DDFS (85.3% vs
47.8%; P < .0001) and OS (80% vs 47%; P < .0001)
compared with those with metastases to the SLN. The
SLN status was the most prognostic of outcome on multi-
variate analysis. In addition to a positive SLN, angiolym-
phatic invasion and ulceration were also predictive of
DDFS, whereas increasing age, Breslow thickness, and
angiolymphatic invasion were associated with OS. How-
ever, when SLN-positive and SLN-negative patients were
analyzed separately, a slightly different picture emerges.
Patient age is only a significant predictor of OS in SLN-
negative patients, and had no impact on DDFS. Among
patients with thick melanomas, angiolymphatic invasion
was a significant predictor of both OS and DDFS among
SLN-positive patients, whereas mitotic rate was a signifi-
cant predictor of both OS and DDFS among SLN-nega-
tive patients. Among SLN-negative patients with T4
melanoma, ulceration was the most significant predictor
of outcome. Despite the Breslow thickness, patients with-
out ulceration or SLN metastases had an extremely good
prognosis, with a 5-year OS>90% and a 5-year DDFS of
95%.
The introduction of the SLN biopsy in 1992 by
Morton et al has substantially changed the surgical man-
agement of cutaneous melanoma.13 Although the poten-
tial benefits of SLN biopsy have been demonstrated in the
interim results from the Multicenter Selective Lymphade-
nectomy Trial-I, this was limited to patients with mela-
noma of between 1.2 mm and 3.5 mm Breslow
thickness.1 Controversy remains regarding the appropri-
ate selection of patients with thin melanoma for SLN bi-
opsy and the need for SLN biopsy in patients with thick
melanoma. Several authors have examined this latter topic
with mixed results.
Before the onset of the SLN biopsy, surgeons
debated but generally felt that ELND played little role in
patients with clinically lymph node-negative melanoma
4 mm in Breslow thickness (T4N0), because these
patients were at such high risk for distant disease. Whether
SLN status has any prognostic or therapeutic value in this
T4N0 subset is unknown. SLN status is often used to
make decisions regarding adjuvant therapy, specifically
the use of high-dose interferon alfa-2b, which is FDA-
approved for high-risk melanoma. Although a positive
SLN is the most common indication for adjuvant high-
dose interferon alpha-2b, high-risk melanoma is also
defined as AJCC stage IIB or C (T4a/bN0M0). There-
fore, regardless of SLN status, patients with thick melano-
mas are already candidates for adjuvant therapy, further
arguing against the need for SLN biopsy among these
patients.
With regard to the prognostic information obtained
from SLN biopsy, previous reports have been mixed
(Table 7). Jacobs et al14 found a difference in median sur-
vival between patients with a negative versus positive
SLN, but this was not statistically significant. Cherpelis
et al15 also found a nonsignificant difference in survival.
Essner et al16 found SLN status to be a predictor of DFS
but not OS. These reports raised concern about the prog-
nostic value of SLN status in thick melanoma.
In contrast, several studies found that SLN status
was 1 of the most significant predictors of outcome
among patients with thick melanoma. Ferrone et al17
described a risk stratification model for this group of
patients using SLN status, age, the presence of ulceration,
and primary tumor thickness to categorize patients into
low-, moderate-, and high-risk groups, and recommended
use of their nomogram rather than the current staging
FIGURE 4. Kaplan-Meier distant disease-free survival analysis
for ulcerated and nonulcerated SLN-positive patients with
thick (T4) primary melanoma is shown.
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system based on the significant survival difference in a
subgroup of patients with T4N0 melanoma previously
thought to have a poor prognosis. The data substantiated
the importance of SLN biopsy in this patient population,
as did a study by Gershenwald et al18 involving 131
patients with T4N0 primary melanomas. They reported
SLN status and ulceration as being the most powerful in-
dicator of DFS and OS and recommended routine per-
formance of this procedure for patients with thick
primary melanoma for risk stratification. Similarly, the
Emory group also found ulceration and SLN status to be
the most powerful predictor of DFS, with SLN status
retaining its significance in predicting OS.19
Our study represents the largest single-institution
study of SLN biopsy in patients with thick T4 melanoma
and clearly demonstrates the accuracy of the prognostic
information gained. The SLN status was the most signifi-
cant predictor of both DDFS and OS in our population,
and ulceration was highly significant among the SLN-
negative patients. This information is not purely aca-
demic, but should help guide adjuvant therapy decisions.
Although in this study the adjuvant use of high-dose inter-
feron alpha-2b was not significantly associated with either
an improved DDFS or OS, the retrospective nature of this
analysis limits any conclusions regarding the impact of
high-dose interferon alpha-2b. However, the 5-year
DDFS and OS of T4 patients who are SLN negative and
have no ulceration (95% and 90%, respectively), most of
whom received no adjuvant therapy, suggests that there
would be little benefit of adjuvant high-dose interferon
alpha-2b in this population. If the SLN is negative but
ulceration is present, the likelihood of distant recurrence
is still significant, and high-dose interferon alpha-2b may
play a role.
In conclusion, SLN biopsy should be the standard
method not only of staging patients with thick melanoma
but also of guiding adjuvant therapy decisions. Assuming
adequate surgical therapy, patients with a negative SLN
have a good prognosis despite the thick primary tumor,
and in the absence of ulceration, they have an extremely
low rate of distant recurrence and excellent OS. Adjuvant
high-dose interferon is clearly not indicated.
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